BioSpace News Archive

AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for adults with moderately to severely active ulcerative colitis, making it the first IL-23 specific inhibitor approved for both moderate to severe ulcerative colitis and moderate to severe Crohn’s disease.

Opthea Limited announced that the retail component of its 1 for 1.22 pro-rata accelerated non-renounceable entitlement offer of new fully paid ordinary shares in Opthea and the issue of options to acquire fully paid ordinary shares in Opthea on a 1 for 3 basis to participants issued New Shares under the Retail Entitlement Offer.

YolTech has partnered with KACTUS, a leading developer serving the biopharmaceutical industry, to advance the commercialization of YolTech’s proprietary DNA editor, YolCas12TM, in Greater China.

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, provided updates on its oncology pipeline at an investor meeting.

The FDA is facing four big target action dates in the final week of June, including one label expansion for a bispecific antibody and another for an investigational gene therapy.

Merck on Monday secured the FDA’s green light for its 21-valent pneumococcal vaccine Capvaxive, which covers serotypes responsible for around 84% of invasive pneumococcal disease cases.

Promising data from the DREAMM-7 and DREAMM-8 trials have revitalized GSK’s blockbuster goals for its antibody-drug conjugate Blenrep, positioned as a second-line treatment for multiple myeloma.

On the heels of last week’s announcements from Foresite Capital and J.P. Morgan Private Capital, Decheng is planning to raise $700 million for its fifth life sciences fund.

Bucking its recent winning streak in oncology, AstraZeneca reported Tuesday that its AKT inhibitor Truqap failed to significantly boost overall survival in patients with triple-negative breast cancer.

Following two deaths due to presumed sepsis, the FDA has placed a partial clinical hold on three trials for Zentalis’ azenosertib including a Phase I in solid tumors, Phase II in platinum-resistant ovarian cancer and Phase II in uterine serous carcinoma.